|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CFAP45 |
Gene summary for CFAP45 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CFAP45 | Gene ID | 25790 |
| Gene name | cilia and flagella associated protein 45 | |
| Gene Alias | CCDC19 | |
| Cytomap | 1q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UL16 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25790 | CFAP45 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 1.43e-02 | 5.96e-01 | -0.0296 |
| 25790 | CFAP45 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 3.94e-03 | 5.15e-01 | -0.0263 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00328861 | Lung | MIAC | regulation of microtubule-based process | 23/967 | 240/18723 | 3.27e-03 | 4.31e-02 | 23 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CFAP45 | SNV | Missense_Mutation | c.421G>A | p.Ala141Thr | p.A141T | Q9UL16 | protein_coding | deleterious(0.01) | benign(0.017) | TCGA-AR-A24P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CFAP45 | SNV | Missense_Mutation | rs753777685 | c.1207C>T | p.Arg403Cys | p.R403C | Q9UL16 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CFAP45 | SNV | Missense_Mutation | c.332N>T | p.Arg111Leu | p.R111L | Q9UL16 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| CFAP45 | SNV | Missense_Mutation | c.1216G>A | p.Glu406Lys | p.E406K | Q9UL16 | protein_coding | deleterious(0) | possibly_damaging(0.764) | TCGA-D8-A1JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| CFAP45 | insertion | In_Frame_Ins | novel | c.45_46insCCATCCAAGGATAATAGCATCAGAGTA | p.Ala15_Ser16insProSerLysAspAsnSerIleArgVal | p.A15_S16insPSKDNSIRV | Q9UL16 | protein_coding | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CFAP45 | deletion | Frame_Shift_Del | novel | c.304delC | p.Leu102Ter | p.L102* | Q9UL16 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CFAP45 | SNV | Missense_Mutation | novel | c.1327C>T | p.Arg443Trp | p.R443W | Q9UL16 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CFAP45 | SNV | Missense_Mutation | novel | c.1131N>C | p.Glu377Asp | p.E377D | Q9UL16 | protein_coding | deleterious(0.03) | possibly_damaging(0.767) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CFAP45 | SNV | Missense_Mutation | novel | c.1519N>A | p.Ala507Thr | p.A507T | Q9UL16 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| CFAP45 | SNV | Missense_Mutation | novel | c.568N>A | p.Glu190Lys | p.E190K | Q9UL16 | protein_coding | deleterious(0) | possibly_damaging(0.487) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |